Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Incyte Corporation Stories

2014-01-16 08:27:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 16, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Eli Lilly & Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), Incyte Corporation (NASDAQ: INCY), and Varian Medical Systems Inc. (NYSE: VAR). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-11-08 08:25:10

NEW YORK, November 8, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Endo Health Solutions Inc. (NASDAQ: ENDP), Bristol-Myers Squibb Co. (NYSE: BMY), Express Scripts Holding Company (NASDAQ: ESRX), AbbVie Inc. (NYSE: ABBV), and Incyte Corporation (NASDAQ: INCY). Today's readers may access these reports free of charge - including full price targets,...

2013-11-05 12:28:52

TUCSON, Ariz., Nov. 5, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Incyte Corporation to collaborate on the development of companion diagnostic tests for Incyte's oncology drug programs, beginning with the Incyte IDO1 inhibitor program. As part of the agreement, Ventana will support Incyte's personalized medicine healthcare strategies for cancer drug development using its vast...

2013-07-29 12:26:21

LONDON, July 29, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Friday, July 26, 2013, shares of biotech companies ended mostly lower even as the broader market posted gains. The major movers in the industry included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Geron Corporation (NASDAQ: GERN), Incyte Corporation (NASDAQ: INCY), and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). AAAResearchReports.com has released...

2013-06-13 08:27:06

- Results from 52-week study presented at EULAR 2013 - MADRID, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with active rheumatoid arthritis (RA). Baricitinib, formerly LY3009104 (INCB28050), is an orally available Janus kinase (JAK) inhibitor being studied for use in the treatment of...

2013-04-23 16:25:08

NEW YORK, April 23, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased Incyte Corporation ("Incyte" or the "Company") (NasdaqGS: INCY) stock between April 26, 2012 and August 1, 2012 (the "Class Period"). (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO ) For more information, click here: http://zlk.9nl.com/incyte-incy/....

2013-02-20 08:28:47

LONDON, February 20, 2013 /PRNewswire/ -- Small-cap biotech stocks can provide big returns when they have a blockbuster drug in their portfolio. As in the case of Incyte Corporation (NASDAQ: INCY), the stock provided steep returns while the company's fortune is dependent on just one drug. The company announced strong Q4 results and provided robust outlook for the future performance. Arena Pharmaceuticals Inc. (NASDAQ: ARNA) also made impressive move on the strength of its...

2012-11-21 12:23:07

CHICAGO, Nov. 21, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Incyte Corporation (Nasdaq:INCY), Eli Lilly and Company (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT) and Express Scripts Holding Company (Nasdaq:ESRX). (Logo:...

2012-11-13 16:25:53

WASHINGTON, Nov. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase (JAK) inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to treatment with methotrexate. Additionally, Magnetic Resonance Imaging (MRI) technology was used in a sub-study to examine the effect of...

2012-08-03 02:26:54

VANCOUVER, British Columbia, Aug. 3, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Bristol Myers Squibb (NYSE:BMY), Sealed Air (NYSE:SEE), Symantec (NASDAQ:SYMC), Morgan Stanley (NYSE:MS), Dow Chemical (NYSE:DOW), and Incyte (NASDAQ:INCY). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)...